Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Allogene Therapeutics, Inc is a biotechnology business based in the US. Allogene Therapeutics shares (ALLO) are listed on the NASDAQ and all prices are listed in US Dollars. Allogene Therapeutics employs 264 staff and has a market cap (total outstanding shares value) of USD$4.4 billion.
Since the stock market crash in March caused by coronavirus, Allogene Therapeutics's share price has had significant positive movement.
Its last market close was USD$33.01, which is 21.21% up on its pre-crash value of USD$26.01 and 89.39% up on the lowest point reached during the March crash when the shares fell as low as USD$17.43.
If you had bought USD$1,000 worth of Allogene Therapeutics shares at the start of February 2020, those shares would have been worth USD$869.71 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,510.21.
|Latest market close||USD$33.01|
|52-week range||USD$17.43 - USD$55|
|50-day moving average||USD$34.1903|
|200-day moving average||USD$38.4596|
|Wall St. target price||USD$51.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.07|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||7.88%|
|1 month (2020-10-30)||-2.68%|
|3 months (2020-08-28)||-5.66%|
|6 months (2020-05-29)||-31.46%|
|1 year (2019-11-29)||17.14%|
|2 years (2018-11-30)||5.53%|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-16.52%|
|Return on equity TTM||-27.92%|
|Market capitalisation||USD$4.4 billion|
TTM: trailing 12 months
There are currently 10.6 million Allogene Therapeutics shares held short by investors – that's known as Allogene Therapeutics's "short interest". This figure is 5.1% up from 10.1 million last month.
There are a few different ways that this level of interest in shorting Allogene Therapeutics shares can be evaluated.
Allogene Therapeutics's "short interest ratio" (SIR) is the quantity of Allogene Therapeutics shares currently shorted divided by the average quantity of Allogene Therapeutics shares traded daily (recently around 778845.03311258). Allogene Therapeutics's SIR currently stands at 13.59. In other words for every 100,000 Allogene Therapeutics shares traded daily on the market, roughly 13590 shares are currently held short.
However Allogene Therapeutics's short interest can also be evaluated against the total number of Allogene Therapeutics shares, or, against the total number of tradable Allogene Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Allogene Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Allogene Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1259% of the tradable shares (for every 100,000 tradable Allogene Therapeutics shares, roughly 126 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Allogene Therapeutics.
Find out more about how you can short Allogene Therapeutics stock.
We're not expecting Allogene Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Allogene Therapeutics's shares have ranged in value from as little as $17.43 up to $55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allogene Therapeutics's is 1.6311. This would suggest that Allogene Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.